Advanced Solid Tumor Clinical Trials in St Louis, Missouri

23 studies are recruiting for advanced solid tumor in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University, School of Medicine, St Louis, Missouri

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

3. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

4. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

5. A Study of KK2269 in Adult Participants With Solid Tumors

   This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary obje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   32 in total

   Run by

   Kyowa Kirin Co., Ltd.

   See if you can join NCT06266299 on ClinicalTrials.gov

6. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

   Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   14 in total

   Run by

   Adcendo ApS

   See if you can join NCT06597721 on ClinicalTrials.gov

7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine in St. Louis, St Louis, Missouri

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

8. Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1011, Washington University, St Louis, Missouri

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

9. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University in St Louis, St Louis, Missouri

   Locations

   31 in total

   Run by

   BeOne Medicines

   See if you can join NCT07222267 on ClinicalTrials.gov

10. A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safet…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    17 in total

    Run by

    BeOne Medicines

    See if you can join NCT07414836 on ClinicalTrials.gov

11. SLV-154 Treatment of Advanced Cancers

    This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    10 in total

    Run by

    Solve Therapeutics

    See if you can join NCT06771219 on ClinicalTrials.gov

12. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #110, St Louis, Missouri

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

13. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #110, St Louis, Missouri

    Locations

    15 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06974110 on ClinicalTrials.gov

14. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    21 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06997029 on ClinicalTrials.gov

15. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    29 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

16. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #6, St Louis, Missouri

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

17. XTX301 in Patients With Advanced Solid Tumors

    This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    12 in total

    Run by

    Xilio Development, Inc.

    See if you can join NCT05684965 on ClinicalTrials.gov

18. A Study of YL201 in Patients With Advanced Solid Tumors

    This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    008, St Louis, Missouri

    Locations

    45 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT05434234 on ClinicalTrials.gov

19. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

    This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 to 89

    Site

    Washington University - Siteman Cancer Center, St Louis, Missouri

    Locations

    57 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06253130 on ClinicalTrials.gov

20. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

    A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, St Louis, Missouri

    Locations

    10 in total

    Run by

    Plexium, Inc.

    See if you can join NCT07284186 on ClinicalTrials.gov

21. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    28 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

22. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    14 in total

    Run by

    Fate Therapeutics

    See if you can join NCT06241456 on ClinicalTrials.gov

23. A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

    This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical …

    Stage

    Phase 2

    Ages

    0 to 25

    Site

    St. Louis Children's Hospital, St Louis, Missouri

    Locations

    35 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT04775485 on ClinicalTrials.gov